Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M9,378Revenue (TTM) $M406Net Margin (%)-27.0Altman Z-Score29.5
Enterprise Value $M8,786EPS (TTM) $-0.8Operating Margin %-27.6Piotroski F-Score4
P/E(ttm)--Beneish M-Score-0.7Pre-tax Margin (%)-27.0Higher ROA y-yY
Price/Book14.110-y EBITDA Growth Rate %-3.7Quick Ratio5.4Cash flow > EarningsY
Price/Sales22.55-y EBITDA Growth Rate %-3.6Current Ratio5.9Lower Leverage y-yY
Price/Free Cash Flow--y-y EBITDA Growth Rate %--ROA % (ttm)-12.5Higher Current Ratio y-yN
Dividend Yield %--PEG--ROE % (ttm)-16.2Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M142ROIC % (ttm)-279.0Gross Margin Increase y-yY

Gurus Latest Trades with SGEN

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
Current Price Change from Average Comment Current Shares
SGENJoel Greenblatt 2016-09-30 Reduce-0.01%$40.15 - $56.57
$ 66.7141%Reduce -72.60%8,242
SGENGeorge Soros 2016-09-30 Reduce-0.01%$40.15 - $56.57
$ 66.7141%Reduce -70.43%4,347
SGENGeorge Soros 2016-06-30 Buy 0.02%$32.95 - $43.78
$ 66.7176%New holding14,700
SGENJoel Greenblatt 2016-06-30 Buy 0.01%$32.95 - $43.78
$ 66.7176%New holding30,082
SGENVanguard Health Care Fund 2015-12-31 Sold Out -0.01%$37.16 - $45.52
$ 66.7160%Sold Out0
SGENVanguard Health Care Fund 2015-06-30 Buy 0.02%$34.03 - $49.63
$ 66.7162%New holding170,125
SGENFirst Eagle Investment 2010-03-31 Sold Out -0.01%$9.34 - $12.59
$ 66.71515%Sold Out0
SGENFirst Eagle Investment 2009-12-31 Buy 0.01%$8.74 - $13.16
$ 66.71588%New holding67,373
SGENBill Gates 2009-09-30 Sold Out -0.39%$8.75 - $14.8
$ 66.71471%Sold Out0
SGENFirst Eagle Investment 2009-06-30 Sold Out -0.01%$8.18 - $10.34
$ 66.71632%Sold Out0
SGENFirst Eagle Investment 2009-03-31 Add$7.23 - $10.36
$ 66.71610%Add 40.00%70,000
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

SGEN is held by these investors:

Premium Most recent portfolio changes are included for Premium Members only!

SGEN: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
DRACHMAN JONATHAN GCMO & EVP, R & D 2016-11-09Sell7,751$66.75-0.73view
BAKER FELIXDirector, 10% Owner 2016-11-08Buy382,500$59.3611.62view
SIEGALL CLAY BPresident and CEO 2016-11-07Sell14,465$58.4313.4view
LIPPMAN MARC EDirector 2016-11-07Sell1,000$57.7514.74view
BAKER FELIXDirector, 10% Owner 2016-11-03Buy198,433$56.4317.42view
BAKER FELIXDirector, 10% Owner 2016-11-03Buy1,030,629$56.1318.05view
DRACHMAN JONATHAN GCMO & EVP, R & D 2016-11-01Sell3,418$51.7428.06view
SIEGALL CLAY BPresident and CEO 2016-10-06Sell14,465$54.4121.78view
DRACHMAN JONATHAN GCMO & EVP, R & D 2016-09-22Sell2,249$56.7516.76view
DOBMEIER ERICCOO 2016-09-14Sell22,918$54.0422.61view

Quarterly/Annual Reports about SGEN:

News about SGEN:

Articles On GuruFocus.com
Insiders Buy Herbalife, Sell MasterCard Nov 05 2016 
Insiders Roundup: Theravance Biopharma, Western Gas, Upland Software Mar 18 2016 
Top Insider Trades of the Past Week Feb 19 2016 
Insiders Are Buying Barnes & Noble Sep 18 2015 
Vanguard Health Care Fund Buys Two New Stakes in Second Quarter Aug 06 2015 
Insiders keep on buying Macerich Co and Seattle Genetics May 22 2015 
Insiders new buys : ZU, SGEN, MAC, SHLD, TBRA May 12 2015 
Seattle Genetics: Can Record Growth From Its Licenses Oct 28 2014 
Seattle Genetics: Can Record Sustained Growth From Royalty Aug 31 2014 
Will ImmunoGen’s Q4 Earnings Disappoint Again? Jul 30 2014 

More From Other Websites
Seattle Genetics and Bristol-Myers Squibb Highlight First Data from Phase 1/2 Study Evaluating... Dec 05 2016
Seattle Genetics Highlights Long-Term Follow-Up Data from ADCETRIS® (Brentuximab Vedotin) in T-Cell... Dec 05 2016
Seattle Genetics Highlights Phase 1 Vadastuximab Talirine (SGN-CD33A; 33A) Data Presentations,... Dec 05 2016
1:54 am Seattle Genetics presents data from Phase 2 study evaluating ADCETRIS; demonstrates active... Dec 05 2016
Takeda and Seattle Genetics Report Positive Phase 3 ALCANZA Clinical Trial Data of ADCETRIS®... Dec 03 2016
Takeda and Seattle Genetics Report Positive Phase 3 ALCANZA Clinical Trial Data of ADCETRIS®... Dec 03 2016
Takeda and Seattle Genetics Report Positive Phase 3 ALCANZA Clinical Trial Data of ADCETRIS®... Dec 03 2016
Seattle Genetics Presents Phase 1b Data from Vadastuximab Talirine (SGN-CD33A; 33A) in Combination... Dec 03 2016
Seattle Genetics Presents Data from Phase 2 Study Evaluating ADCETRIS® (Brentuximab Vedotin) in... Dec 03 2016
ETFs with exposure to Seattle Genetics, Inc. : December 2, 2016 Dec 02 2016
Biotechs Aerie, Medicines Co., Tesaro Could Rocket, Or Be Bought: RBC Dec 01 2016
Hedge Funds Are Coming Back to Seattle Genetics, Inc. (SGEN) Dec 01 2016
[$$] Three Biotechs With Bullish Insider Buying Dec 01 2016
Seattle Genetics to Webcast Investor and Analyst Event at American Society of Hematology Annual... Nov 29 2016
[$$] Biotech M&A Could Surge Under Trump Nov 15 2016
Could Trump 'Make Drug Development Great Again'? Nov 14 2016
Incyte Corporation (INCY), Seattle Genetics, Inc. (SGEN) & Two More: Top Healthcare Hedge Fund Loves... Nov 14 2016
Massive Icahn Trades Highlight Huge Insider Buying: Hertz Global, Herbalife, CBRE, Seattle Genetics... Nov 13 2016
Seattle Genetics moves up FDA timeline for cash cow drug Adcetris Nov 11 2016
Could Trump Tax Cut Plans, Republican Congress Spur Biotech M&A? Nov 10 2016

Add Notes, Comments

If you want to ask a question or report a bug, please create a support ticket.
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)